Search | Page 30 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. AML Therapy With Irradiated Allogeneic Cells

    ... must not be a candidate for an allo-hematopoietic stem cell transplant (HSCT) Patient must have a partially (>= 3/6 class I ...

    Clinical Trial last updated 06/13/2016 - 3:14pm.

  2. "Moderate" dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolution

    ... sibling donor or are too old for hematopoietic stem cell transplant . Approximately two thirds of patients successfully respond ...

    Research Review last updated 05/02/2016 - 9:13am.

  3. Duane Draper builds supportive community to help him with MDS and bone marrow transplant

    ... as well. Procrit shots increased his red blood cell production while he explored his options for treatment. A ... Center in Boston told him that he qualified for a full stem cell transplant , and they started searching for a donor. Neither his ...

    Patient Chronicle last updated 09/09/2014 - 10:02am.

  4. Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant

    ... side effects and best dose of selinexor when given after stem cell transplant in treating patients with acute myeloid leukemia that is at ...

    Clinical Trial last updated 04/29/2016 - 10:38am.

  5. Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies

    ... use short-duration tacrolimus after a peripheral blood stem cell transplant in certain malignancies that are considered difficult to ...

    Clinical Trial last updated 05/03/2016 - 11:45am.

  6. Randomized Allogeneic Azacitidine Study

    ... with AML, CMML, or MDS after an allogeneic (donor) stem cell transplant . The safety of this drug will also be studied. ...

    Clinical Trial last updated 05/03/2016 - 11:08am.

  7. A Phase II Study of 5-Azacitidine and Sargramostim as Maintenance Treatment After Definitive Therapy for Poor-risk AML or MDS

    ... are in remission after definitive treatment with either stem cell transplant or cytarabine-based consolidation chemotherapy . ...

    Clinical Trial last updated 05/03/2016 - 10:38am.

  8. Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS

    ... of two novel conditioning therapies for hematopoietic stem cell transplant (HSCT). The primary focus of both the investigators' ...

    Clinical Trial last updated 05/03/2016 - 10:36am.

  9. Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies

    ... chemotherapy and/or arising from MDS, Langerhan's cell histiocytosis, any disease beyond first remission; or, Myelodysplastic ... relapse (including relapse post autologous hematopoietic stem cell transplant ). Double hit lymphomas in first remission or more ...

    Clinical Trial last updated 06/06/2016 - 12:58pm.

  10. Telomere Length and Allogeneic Hematopoietic Cell Transplantation for Severe Aplastic Anemia

    ... Telomere length in hematopoietic stem cell transplantation for severe aplastic anemia: is it ready for "prime time"? ...

    Research Review last updated 05/02/2016 - 9:13am.